NTX250: A Modular mRNA-Based Immunotherapy Platform for HPV-Associated Cancers with Broad Applicability.

Area of Science:

• Oncology
• Immunology
• Vaccinology

Background:

• High-risk human papillomavirus (HPV) drives significant cancer development, including cervical, oropharyngeal, head and neck, and anogenital cancers.
• Current treatments like LEEP remove lesions but fail to eradicate persistent HPV infections, leaving patients at risk for recurrence and new malignancies.
• Existing prophylactic HPV vaccines have limitations in accessibility and uptake, necessitating alternative therapeutic strategies.

Purpose of the Study:

• To introduce NTX250, an innovative mRNA-based therapeutic platform for treating persistent HPV infections and associated cancers.
• To evaluate the efficacy of NTX250 in preclinical models of HPV16-associated tumors.
• To demonstrate the potential of this platform as a versatile immunotherapeutic approach.

Main Methods:

• NTX250 utilizes mRNA encoding HPV16 E6-E7 antigens and immunomodulators (human interleukin-12 p70 and engineered human LIGHT).
• Co-delivery of mRNAs is achieved via lipid and ionizable peptoid nanoparticles (Nutshell™ formulation) for intralesional administration.
• Preclinical evaluation involved HPV16-transformed tumor-bearing models.

Main Results:

• Localized NTX250 administration led to complete regression of established HPV16-driven tumors.
• The treatment induced durable, antigen-specific immune memory, crucial for long-term protection.
• The modular nanoparticle approach demonstrated adaptability for targeting other tumor antigens.

Conclusions:

• NTX250 represents a potent, non-surgical immunotherapeutic strategy for HPV-associated malignancies.
• This mRNA nanoparticle platform offers a versatile approach for developing immunotherapies beyond HPV, targeting various cancers.
• The findings support the potential of NTX250 for inducing robust and specific anti-tumor responses.